[ { "@graph" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#pubInfo" } ] } ], "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#Head" }, { "@graph" : [ { "@id" : "http://identifiers.org/drugbank/DB01104", "@type" : [ "https://w3id.org/biolink/vocab/Drug" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "sertraline" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] }, { "@id" : "http://purl.obolibrary.org/obo/MONDO_0008114", "@type" : [ "https://w3id.org/biolink/vocab/Disease" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "obsessive-compulsive disorder" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#association", "@type" : [ "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/MONDO_0008114" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "http://identifiers.org/drugbank/DB01104" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78]." } ], "https://w3id.org/biolink/vocab/aggregator_knowledge_source" : [ { "@id" : "https://w3id.org/biolink/infores/knowledge-collaboratory" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/has_population_context" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#context" } ], "https://w3id.org/biolink/vocab/publications" : [ { "@id" : "http://www.ncbi.nlm.nih.gov/pubmed/30101713" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "http://purl.obolibrary.org/obo/NCIT_C94303" } ] }, { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#context", "@type" : [ "https://w3id.org/biolink/vocab/Cohort" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "adults" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Cohort" } ] } ], "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-7641-6446" } ] } ], "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk", "http://www.w3.org/ns/prov#generatedAtTime" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2022-09-16T11:53:49.145453" } ], "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1501-1082" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "M7gktdbiNUgTK9MQ2fCjlG/ldf2/3FUNLKyY44iK8dgCUk1BtoZyE/3UjniS47B1kyn26A1ZK3GuJpZNespnWE32XB5m9b9lWhYhus1sDOtoc7hKqZH7Dz045S95TwJCr1s9hbEVs3ZM7rhVpsiv8utyodP/Yl+E3enS9DLotGM=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk" } ] }, { "@id" : "https://w3id.org/biolink/vocab/", "http://purl.org/pav/version" : [ { "@value" : "2.3.0" } ] } ], "@id" : "http://purl.org/np/RAZFqdakeGaMVnGpjTC_tRPZ1trWEeMiq8gy2y06u-nnk#pubInfo" } ]